

# THNR

## Amplify Weight Loss Drug & Treatment ETF

### Analyst Report

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

### ESG Themes and Scores

7.17/10

ESG Rate

78.2%

Global Percentile

92.38%

Peer Percentile

### Performance Data

	THNR	ETF Database Category Average	Factset Segment Average
1 Month	2.75%	1.64%	0.92%
3 Month	-6.30%	2.54%	-2.10%
YTD Return	3.68%	2.39%	1.23%
1 Year Return	N/A	5.83%	0.00%
3 Year Return	N/A	0.43%	0.00%
5 Year Return	N/A	0.10%	0.00%

### Top 5 Holdings

Symbol	Holding	% Assets
LLY	Eli Lilly and Company	16.72%
NVO	Novo Nordisk A/S Sponsored ADR Class B	12.26%
ROG	Roche Holding Ltd Dividend Right Cert.	5.83%
AMGN	Amgen Inc.	5.81%
TMO	Thermo Fisher Scientific Inc.	5.74%

### Vitals

Issuer	Amplify Investments
Brand	Amplify
Structure	N/A
Expense Ratio	0.59%
Inception	May 21, 2024
Index Tracked	VettaFi Weight Loss Drug Index - Benchmark TR Net

### ETF Database Themes

Category	N/A
Asset Class	Equity
Asset Class Size	N/A
Asset Class Style	N/A

### FactSet Classifications

Segment	Equity: Developed Markets Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Vanilla
Weighting	Tiered

